Know Cancer

or
forgot password

A Randomized Trial of Hypofractionated Radiotherapy Post-Lumpectomy in Women With Node Negative Breast Cancer


Phase 3
N/A
N/A
Open (Enrolling)
Female
Breast Cancer

Thank you

Trial Information

A Randomized Trial of Hypofractionated Radiotherapy Post-Lumpectomy in Women With Node Negative Breast Cancer


Inclusion Criteria:



1. The female patient has a histological diagnosis of invasive carcinoma of the breast,
and no evidence of metastatic disease.

2. Has had a lumpectomy (including segmental resection and partial mastectomy), that is,
surgical excision of the tumour with a rim of normal tissue.

3. Patient has not had an axillary dissection, OR for patients who have had an axillary
dissection, all nodes are negative for metastatic disease.

Exclusion Criteria:

1. Tumour greater than 5 cm in greatest diameter on pathological examination.

2. The presence of invasive or intraductal (noninvasive) breast cancer involving the
surgical margins.

3. Clinical evidence prior to surgery of infiltration of the skin of the involved breast
such as edema, ulceration, or fixation of the tumour to underlying muscle, or
inflammatory breast cancer.

4. Bilateral malignancy of the breast (synchronous or metachronous).

5. More than one primary invasive tumour in the same breast.

6. Previous surgery for breast cancer.

7. Pathological status of axilla is unknown.

8. Status for adjuvant systemic therapy not determined.

9. For patients not treated with adjuvant chemotherapy: unable to commence radiation
therapy within 16 weeks of last surgical procedure on the breast.

10. For patients treated with adjuvant chemotherapy: unable to commence radiation
therapy within 8 weeks of the last dose of chemotherapy.

11. Serious nonmalignant disease (eg. cardiovascular, renal, etc.) which would preclude
surgical or radiation treatment.

12. Currently pregnant or lactating.

13. Breast deemed too large to permit satisfactory radiation (ie. separation > 25 cm).

14. Previous concomitant malignancies of any type except squamous, or basal cell
carcinomas of the skin, or carcinoma \fIin situ\fR of the cervix which have been
effectively treated.

15. Geographic inaccessibility for follow-up.

16. Psychiatric or addictive disorders which preclude obtaining informed consent or
adherence to the protocol.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Local breast recurrence

Principal Investigator

Tim Whelan, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Juravinski Cancer Centre

Authority:

Canada: Health Canada

Study ID:

OCOG-1993-hypo

NCT ID:

NCT00156052

Start Date:

April 1993

Completion Date:

Related Keywords:

  • Breast Cancer
  • Breast Cancer
  • Hypofractionated Radiotherapy
  • Lumpectomy
  • Breast Neoplasms

Name

Location